ArcticZymes Technologies — Board/Management Information 2010

Mar 10, 2010

Svein Lien appointed new CEO of Biotec Pharmacon ASA

(Oslo/Tromsø, 10 March, 2010) Svein Lien has been appointed new CEO of Biotec

Pharmacon, following Lars Viksmoen's decision to resign after 3 years as CEO.

Svein Lien will assume the position with effect from 15 March, 2010.

Svein Lien (55) joins the company with a financial background and extensive

experience from technology- and diagnostics businesses, most recently as CEO of

Axis-Shield plc, the diagnostic company listed in London and Oslo.

"The company has gone through a hectic and challenging few years. Having

identified a likely root cause for the disappointing clinical phase III results

with SBG in wound care, I believe now is the right time for a new management to

re-establish a strategic platform and pursue the pharmaceutical opportunities in

parallel with continued development of the very successful marine enzyme

business", says CEO Lars Viksmoen.

"Lars has made significant contributions to the company. We regret his decision

to leave the organization, but respect his wish to step aside and let others

take leadership as the company enters a new phase of its pharmaceutical

development program", says Chairman of the Board Svein Mathisen in Biotec

Pharmacon.

Further, Svein Mathisen added: "With Svein Lien we have secured an experienced

CEO with the skills and profile necessary to leverage the opportunities in our

business portfolio".

"I am very much looking forward to this challenge" Svein Lien says.  "I know the

company very well from several years as a Board Member and have always been very

confident with the technology platform and admired the highly skilled and

talented organization. I also have a strong faith in the opportunities created

by the close relation to the research community in Tromsø.  We will need some

more time to conclude on the roote cause behind the disappointing Phase III

results and to clarify the strategic route forward. Following that we will

inform the market, most likely via a capital market day in Q2."

Following divestment of Immunocorp Animal Health in 2008 and Immunocorp Consumer

Health at the end of 2009 Biotec Pharmacon has narrowed its strategic focus to

two core business areas; pharmaceutical development and marine biochemicals.

Whereas pharmaceutical development yet is in a research & development phase,

Biotec Marine Biochemicals is a profitable, high-growth business, centered and

specialized around cold-adapted marine enzymes for the molecular biology and

diagnostics markets.

For further information, please contact:

Chairman of the Board, Svein Mathisen, tel: +46 462868567

CEO, Lars Viksmoen, tel: +47 40620870

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

[HUG#1392482]